胃と腸59巻10号

2024年10月発行

増大号 炎症性腸疾患2024

主題 炎症性腸疾患の病態

炎症性腸疾患のサイトカインプロファイル

著者： 横山佳浩¹ 菓裕貴¹ 仲瀬裕志¹

所属機関： ¹1）札幌医科大学医学部消化器内科学講座

ページ範囲：P.1339 - P.1346

文献概要

要旨●炎症性腸疾患（IBD）は潰瘍性大腸炎（UC）とCrohn病（CD）の2つに大きく分けられる．UCはTh2細胞優位，CDはTh1細胞優位の病態と考えられていたが，近年ではそれ以外にもTh17細胞やTh9細胞，B細胞，そして自然免疫などのさまざまな免疫異常がその病態を形成していることが明らかとなった．さらに動物実験モデルの検討から，IBDは発症の早期と後期において異なるサイトカインパターンを示していること，ヒトサンプルを用いたデータでも罹患時期および個々人において異なるサイトカインプロファイルを有していることが明らかとなった．このような多様性に富んだIBDの病態を理解し，時期と個々人に応じた個別化医療を実践していくことが今後の課題である．

参考文献

1）Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol　56：489-526, 2021

2）Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity　50：992-1006, 2019

3）Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet　47：979-986, 2015

4）Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD：immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol　16：185-196, 2019

5）Nakase H, Sato N, Mizuno N, et al. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev　21：103017, 2022

6）Baumgart DC, Le Berre C. Newer biologic and small-molecule therapies for inflammatory bowel disease. N Engl J Med　385：1302-1315, 2021

7）Schmidt C, Grunert PC, Stallmach A. An update for pharmacologists on new treatment options for inflammatory bowel disease：the Clinicians' perspective. Front Pharmacol　12：655054, 2021

8）Pickert G, Neufert C, Leppkes M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med　206：1465-1472, 2009

9）Lee JS, Tato CM, Joyce-Shaikh B, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity　43：727-738, 2015

10）Maxwell JR, Zhang Y, Brown WA, et al. Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity　43：739-750, 2015

11）Shih VFS, Cox J, Kljavin NM, et al. Homeostatic IL-23 receptor signaling limits Th17 response through IL-22-mediated containment of commensal microbiota. Proc Natl Acad Sci USA　111：13942-13947, 2014

12）Grizotte-Lake M, Zhong G, Duncan K, et al. Commensals suppress intestinal epithelial cell retinoic acid synthesis to regulate interleukin-22 activity and prevent microbial dysbiosis. Immunity　49：1103-1115, e6, 2018

13）Schiering C, Wincent E, Metidji A, et al. Feedback control of AHR signalling regulates intestinal immunity. Nature　542：242-245, 2017

14）Kole A, He J, Rivollier A, et al. Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis. J Immunol　191：2771-2779, 2013

15）Cosín-Roger J, Ortiz-MasiáD, Calatayud S, et al. The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD. Mucosal Immunol　9：986-998, 2016

16）Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol　10：170-181, 2010

17）Chinen T, Kannan AK, Levine AG, et al. An essential role for the IL-2 receptor in T reg cell function. Nat Immunol　17：1322-1333, 2016

18）Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature　513：564-568, 2014

19）Macpherson AJ, Yilmaz B, Limenitakis JP, et al. IgA function in relation to the intestinal microbiota. Annu Rev Immunol　36：359-381, 2018

20）Drury B, Hardisty G, Gray RD, et al. Neutrophil extracellular traps in inflammatory bowel disease：pathogenic mechanisms and clinical translation. Cell Mol Gastroenterol Hepatol　12：321-333, 2021

21）Bain CC, Bravo-Blas A, Scott CL, et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol　15：929-937, 2014

22）Zigmond E, Varol C, Farache J, et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity　37：1076-1090, 2012

23）Yao H, Tang G. Macrophages in intestinal fibrosis and regression. Cell Immunol　381：104614, 2022

24）Chieppa M, Rescigno M, Huang AYC, et al. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. J Exp Med　203：2841-2852, 2006

25）Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology　129：50-65, 2005

26）Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med　203：2473-2483, 2006

27）Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature　448：427-434, 2007

28）Forkel M, van Tol S, Höög C, et al. Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established Crohn's disease and ulcerative colitis. J Crohns Colitis　13：67-78, 2019

29）Gomez-Bris R, Saez A, Herrero-Fernandez B, et al. CD4 T-Cell Subsets and the pathophysiology of inflammatory bowel disease. Int J Mol Sci　24：2696, 2023

30）Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol　20：970-979, 2019

31）Arnold IC, Mathisen S, Schulthess J, et al. CD11c（＋） monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23. Mucosal Immunol　9：352-363, 2016

32）Stockinger B, Omenetti S. The dichotomous nature of T helper 17 cells. Nat Rev Immunol　17：535-544, 2017

33）de Souza HSP, Fiocchi C. Immunopathogenesis of IBD：current state of the art. Nat Rev Gastroenterol Hepatol　13：13-27, 2016

34）Shohan M, Sabzevary-Ghahfarokhi M, Bagheri N, et al. Intensified Th9 Response is associated with the immunopathogenesis of active ulcerative colitis. Immunol Invest　47：700-711, 2018

35）Wang X, Zhu Y, Zhang M, et al. Ulcerative colitis is characterized by a decrease in regulatory B Cells. J Crohns Colitis　10：1212-1223, 2016

36）Mizoguchi E, Mizoguchi A, Bhan AK. Role of cytokines in the early stages of chronic colitis in TCR alpha-mutant mice. Lab Invest　76：385-397, 1997

37）Mizoguchi A, Mizoguchi E, Chiba C, et al. Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease. J Exp Med　183：847-856, 1996

38）Spencer DM, Veldman GM, Banerjee S, et al. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology　122：94-105, 2002

39）Bamias G, Martin C, Mishina M, et al. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology　128：654-666, 2005

40）Collett A, Higgs NB, Gironella M, et al. Early molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in mdr1a（-/-）mice. Inflamm Bowel Dis　14：620-631, 2008

41）Alex P, Zachos NC, Nguyen T, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis　15：341-352, 2009

42）Boehm F, Martin M, Kesselring R, et al. Deletion of Foxp3＋ regulatory T cells in genetically targeted mice supports development of intestinal inflammation. BMC Gastroenterol　12：97, 2012

43）Eftychi C, Schwarzer R, Vlantis K, et al. Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment. Immunity　51：367-380, e4, 2019

44）Mavroudis G, Magnusson MK, Isaksson S, et al. Mucosal and systemic immune profiles differ during early and late phases of the disease in patients with active ulcerative colitis. J Crohns Colitis　13：1450-1458, 2019

45）Lees CW, Barrett JC, Parkes M, et al. New IBD genetics：common pathways with other diseases. Gut　60：1739-1753, 2011

46）Fuyuno Y, Yamazaki K, Takahashi A, et al. Genetic characteristics of inflammatory bowel disease in a Japanese population. J Gastroenterol　51：672-681, 2016

47）Leppkes M, Neurath MF. Cytokines in inflammatory bowel diseases - update 2020. Pharmacol Res　158：104835, 2020

48）Butera A, Di Paola M, Vitali F, et al. IL-13 mRNA tissue content identifies two subsets of adult ulcerative colitis patients with different clinical and mucosa-associated microbiota profiles. J Crohns Colitis　14：369-380, 2020

49）West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med　23：579-589, 2017

50）Bertani L, Baglietto L, Antonioli L, et al. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol　86：1296-1305, 2020